RemeGen's Telitacicept Achieves 55% Proteinuria Reduction in Phase 3 IgA Nephropathy Trial
Key Insights
RemeGen's telitacicept demonstrated a 55% reduction in 24-hour urine protein-to-creatinine ratio at 39 weeks compared to placebo in a Phase 3 IgA nephropathy (search) trial.
The multicenter, randomized, double-blind, placebo-controlled study involved 318 participants and successfully met its primary endpoint of reducing proteinuria (search).
RemeGen plans to submit a Biologics License Application to China's National Medical Products Administration for IgA nephropathy (search) indication.
RemeGen Co., Ltd has achieved a significant milestone in treating IgA nephropathy (search) (IgAN), with its investigational drug telitacicept meeting the primary endpoint in Stage A of a Phase 3 clinical trial in China. The study demonstrated a 55% reduction in 24-hour urine protein-to-creatinine ratio at 39 weeks compared with placebo, marking a substantial therapeutic advance for this progressive kidney disease.
Trial Design and Results
The multicenter, randomized, double-blind, placebo-controlled clinical trial enrolled 318 participants with IgA nephropathy (search). In Stage A of the Phase 3 study, telitacicept successfully achieved its primary endpoint of reducing proteinuria (search), a key marker of kidney damage and disease progression in IgAN patients.
The 55% reduction in proteinuria (search) represents a clinically meaningful improvement that could translate to better long-term kidney function preservation for patients with this chronic condition.
Regulatory Pathway Forward
Following these positive results, RemeGen is preparing to submit a Biologics License Application (BLA) to the Center for Drug Evaluation of the National Medical Products Administration in China for the IgA nephropathy (search) indication. This regulatory submission represents a critical step toward bringing telitacicept to Chinese patients with IgAN.
Partnership and Development
The telitacicept program is being developed through a collaboration between RemeGen and Vor Biopharma Inc. (VOR), with RemeGen leading the clinical development in China. Vor Biopharma's stock was trading at $2.02, down 2.65% on the Nasdaq following the announcement.
The successful completion of Stage A in this Phase 3 trial positions telitacicept as a potential new treatment option for IgA nephropathy (search) patients, addressing a significant unmet medical need in nephrology.